Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

11,221 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS).
Landgren CO, Chari A, Cohen YC, Spencer A, Voorhees P, Estell JA, Sandhu I, Jenner MW, Williams C, Cavo M, van de Donk NWCJ, Beksac M, Moreau P, Goldschmidt H, Kuppens S, Bandekar R, Clemens PL, Neff T, Heuck C, Qi M, Hofmeister CC. Landgren CO, et al. Among authors: williams c. Leukemia. 2020 Jul;34(7):1840-1852. doi: 10.1038/s41375-020-0718-z. Epub 2020 Feb 5. Leukemia. 2020. PMID: 32024950 Free PMC article. Clinical Trial.
Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study.
Dimopoulos M, Siegel DS, Lonial S, Qi J, Hajek R, Facon T, Rosinol L, Williams C, Blacklock H, Goldschmidt H, Hungria V, Spencer A, Palumbo A, Graef T, Eid JE, Houp J, Sun L, Vuocolo S, Anderson KC. Dimopoulos M, et al. Among authors: williams c. Lancet Oncol. 2013 Oct;14(11):1129-1140. doi: 10.1016/S1470-2045(13)70398-X. Epub 2013 Sep 19. Lancet Oncol. 2013. PMID: 24055414 Clinical Trial.
Carfilzomib or bortezomib in combination with cyclophosphamide and dexamethasone followed by carfilzomib maintenance for patients with multiple myeloma after one prior therapy: results from a multicenter, phase II, randomized, controlled trial (MUKfive).
Yong KL, Hinsley S, Auner HW, Bygrave C, Kaiser MF, Ramasamy K, De Tute RM, Sherratt D, Flanagan L, Garg M, Hawkins S, Williams C, Cavenagh J, Rabin NK, Croft J, Morgan G, Davies F, Owen RG, Brown SR. Yong KL, et al. Among authors: williams c. Haematologica. 2021 Oct 1;106(10):2694-2706. doi: 10.3324/haematol.2021.278399. Haematologica. 2021. PMID: 33910333 Free PMC article. Clinical Trial.
An international, multicenter, prospective, observational study of neutropenia in patients being treated with lenalidomide + dexamethasone for relapsed or relapsed/refractory multiple myeloma (RR-MM).
Leleu X, Terpos E, Sanz RG, Cooney J, O'Gorman P, Minarik J, Greil R, Williams C, Gray D, Szabo Z. Leleu X, et al. Among authors: williams c. Am J Hematol. 2016 Aug;91(8):806-11. doi: 10.1002/ajh.24416. Epub 2016 Jun 8. Am J Hematol. 2016. PMID: 27169523 Free article.
The outcome of unrelated donor stem cell transplantation for patients with multiple myeloma.
Shaw BE, Peggs K, Bird JM, Cavenagh J, Hunter A, Alejandro Madrigal J, Russell NH, Sirohi B, Towlson K, Williams CD, Marks DI; Clinical Trials Committee of the British Society of Blood and Marrow Transplantation. Shaw BE, et al. Br J Haematol. 2003 Dec;123(5):886-95. doi: 10.1046/j.1365-2141.2003.04714.x. Br J Haematol. 2003. PMID: 14632780 Free article.
Etoposide, methylprednisolone, cytarabine and cisplatin successfully cytoreduces resistant myeloma patients and mobilizes them for transplant without adverse effects.
D'Sa S, Yong K, Kyriakou C, Bhattacharya S, Peggs KS, Foulkes B, Watts MJ, Ings SJ, Ardeshna KM, Goldstone AH, Williams CD. D'Sa S, et al. Among authors: williams cd. Br J Haematol. 2004 Jun;125(6):756-65. doi: 10.1111/j.1365-2141.2004.04981.x. Br J Haematol. 2004. PMID: 15180865 Free article.
Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: limited efficacy of graft-versus-tumor activity.
Peggs KS, Mackinnon S, Williams CD, D'Sa S, Thuraisundaram D, Kyriakou C, Morris EC, Hale G, Waldmann H, Linch DC, Goldstone AH, Yong K. Peggs KS, et al. Among authors: williams cd. Biol Blood Marrow Transplant. 2003 Apr;9(4):257-65. doi: 10.1053/bbmt.2003.50009. Biol Blood Marrow Transplant. 2003. PMID: 12720218 Free article. Clinical Trial.
Role of nonmyeloablative allogeneic stem-cell transplantation after failure of autologous transplantation in patients with lymphoproliferative malignancies.
Branson K, Chopra R, Kottaridis PD, McQuaker G, Parker A, Schey S, Chakraverty RK, Craddock C, Milligan DW, Pettengell R, Marsh JC, Linch DC, Goldstone AH, Williams CD, Mackinnon S. Branson K, et al. Among authors: williams cd. J Clin Oncol. 2002 Oct 1;20(19):4022-31. doi: 10.1200/JCO.2002.11.088. J Clin Oncol. 2002. PMID: 12351600
Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen.
Chakraverty R, Peggs K, Chopra R, Milligan DW, Kottaridis PD, Verfuerth S, Geary J, Thuraisundaram D, Branson K, Chakrabarti S, Mahendra P, Craddock C, Parker A, Hunter A, Hale G, Waldmann H, Williams CD, Yong K, Linch DC, Goldstone AH, Mackinnon S. Chakraverty R, et al. Among authors: williams cd. Blood. 2002 Feb 1;99(3):1071-8. doi: 10.1182/blood.v99.3.1071. Blood. 2002. PMID: 11807015 Free article. Clinical Trial.
11,221 results
You have reached the last available page of results. Please see the User Guide for more information.